Iopamidol
Isovue (iopamidol) is a small molecule pharmaceutical. Iopamidol was first approved as Isovue-m 200 on 1985-12-31.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Isovue (generic drugs available since 2023-02-27, discontinued: Scanlux)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iopamidol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ISOVUE-250 | Bracco Diagnostics | N-018735 RX | 1992-07-06 | 1 products, RLD, RS |
| ISOVUE-200 | Bracco Diagnostics | N-018735 RX | 1987-07-07 | 1 products, RLD, RS |
| ISOVUE-M 200 | Bracco Diagnostics | N-018735 RX | 1985-12-31 | 1 products, RLD, RS |
| ISOVUE-300 | Bracco Diagnostics | N-018735 RX | 1985-12-31 | 1 products, RLD, RS |
| ISOVUE-370 | Bracco Diagnostics | N-018735 RX | 1985-12-31 | 1 products, RLD, RS |
| ISOVUE-M 300 | Bracco Diagnostics | N-018735 RX | 1985-12-31 | 1 products, RLD, RS |
| ISOVUE-250 | Bracco Diagnostics | N-020327 RX | 1994-10-12 | 1 products, RLD, RS |
| ISOVUE-300 | Bracco Diagnostics | N-020327 RX | 1994-10-12 | 1 products, RLD, RS |
| ISOVUE-370 | Bracco Diagnostics | N-020327 RX | 1994-10-12 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| isovue | New Drug Application | 2023-04-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | I25.1 | — | — | 2 | 6 | 1 | 9 | |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 6 | — | 6 |
| Chronic renal insufficiency | D051436 | N18 | — | — | — | 4 | — | 4 | |
| Healthy volunteers/patients | — | 2 | 1 | — | 1 | — | 3 | ||
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 3 | — | 3 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 2 | — | 2 |
| Coronary stenosis | D023921 | EFO_1000882 | — | — | — | 2 | — | 2 | |
| Arterial occlusive diseases | D001157 | EFO_0009085 | — | — | — | 2 | — | 2 | |
| Back pain | D001416 | HP_0003418 | M54 | — | — | — | 1 | — | 1 |
| Hypothyroidism | D007037 | EFO_0004705 | E03.9 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | — | 1 | — | — | 1 | ||
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | — | 1 |
| Carotid stenosis | D016893 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injury | D058186 | HP_0001919 | N17 | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | C80 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardio-renal syndrome | D059347 | — | — | — | — | 2 | 2 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 1 | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | 1 | 1 | ||
| Lung neoplasms | D008175 | C34.90 | — | — | — | — | 1 | 1 | |
| Small cell lung carcinoma | D055752 | — | — | — | — | 1 | 1 | ||
| Mesothelioma | D008654 | C45 | — | — | — | — | 1 | 1 | |
| St elevation myocardial infarction | D000072657 | — | — | — | — | 1 | 1 | ||
| Otitis media with effusion | D010034 | EFO_0007415 | H65.3 | — | — | — | — | 1 | 1 |
| Aortic valve stenosis | D001024 | EFO_0000266 | Q25.1 | — | — | — | — | 1 | 1 |
| Abdominal aortic aneurysm | D017544 | EFO_0004214 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | IOPAMIDOL |
| INN | iopamidol |
| Description | Iopamidol is a benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position. It has a role as a radioopaque medium, an environmental contaminant and a xenobiotic. It is a benzenedicarboxamide, an organoiodine compound and a pentol. |
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I |
Identifiers
| PDB | — |
| CAS-ID | 60166-93-0 |
| RxCUI | 5966 |
| ChEMBL ID | CHEMBL1200932 |
| ChEBI ID | 31711 |
| PubChem CID | 65492 |
| DrugBank | DB08947 |
| UNII ID | JR13W81H44 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,300 documents
View more details
Safety
Black-box Warning
Black-box warning for: Isovue
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,441 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more